Shang­hai un­veils plans for bi­o­log­i­cal medicine in­dus­try

China Daily (Canada) - - SHANGHAI - By ZHOU WENTING in Shang­hai zhouwent­[email protected]­nadaily.com.cn

Shang­hai plans to build high­end man­u­fac­tur­ing parks for bi­o­log­i­cal medicine by 2020 to com­ple­ment and de­velop in­ter­ac­tively with Pudong New Area’s Zhangjiang, known as China’s pharma val­ley, ac­cord­ing to a three-year ac­tion plan.

The parks are planned so far in the mu­nic­i­pal­ity’s dis­tricts of Jin­shan and Fengx­ian, as well as Lin­gang area in Pudong based on the ex­ist­ing in­dus­trial parks. They will fo­cus on med­i­cal de­vices, beauty and bio­phar­ma­ceu­ti­cals re­spec­tively, said Cao Hong­ming, di­rec­tor of the bi­o­log­i­cal medicine divi­sion of Shang­hai Mu­nic­i­pal Science and Tech­nol­ogy Com­mis­sion, at a me­dia brief­ing when the com­mis­sion re­leased the Ac­tion Plan to Pro­mote the High Qual­ity De­vel­op­ment of the Bi­o­log­i­cal Medicine In­dus­try in Shang­hai (2018-20) on Wed­nes­day.

En­ter­prises in the in­dus­try are highly con­cen­trated in Zhangjiang, where some com­pa­nies found it hard to ac­quire land sev­eral years ago and now find it even harder to ob­tain a small space for an of­fice, Cao said.

“Ac­tu­ally we’ve suf­fered the out­flow of some projects with good prospects ow­ing to the lim­ited land,” he said.

The ac­tion plan has come up with mea­sures on land ex­pan­sion to­gether with the qual­ity and ca­pac­ity up­grade of Zhangjiang as Shang­hai aims for the con­tin­ued de­vel­op­ment of bi­o­log­i­cal medicine, one of the city’s strate­gic emerg­ing in­dus­tries, and build­ing it­self into a key area for bi­o­log­i­cal medicine.

Shang­hai’s to­tal eco­nomic out­put of bio­med­i­cal medicine reached more than 304 bil­lion yuan ($44 bil­lion) last year, a yearon-year in­crease of more than 5.8 per­cent, sta­tis­tics from the com­mis­sion showed.

Jin­shan, Fengx­ian and Lin­gang were se­lected for the in­dus­trial base and they will be co­or­di­nated at the city level to co­op­er­ate with Zhangjiang and main­tain high­end and green de­vel­op­ment, Cao said.

Liu Xinyu, di­rec­tor of the science and tech­nol­ogy com­mis­sion of Jin­shan dis­trict, said that there are so far 40 en­ter­prises en­gaged in bi­o­log­i­cal medicine in the dis­trict, 14 of which have an an­nual pro­duc­tion value of more than 100 mil­lion yuan.

“In the fu­ture, some projects may carry out re­search and de­vel­op­ment in Zhangjiang,” Liu said.

Wang Guowei, deputy di­rec­tor of the science and tech­nol­ogy com­mis­sion of Fengx­ian dis­trict, said that an in­dus­trial park cov­er­ing an area of 1.8 square kilo­me­ters and spe­cial­iz­ing in bi­o­log­i­cal medicine plus cos­met­ics was es­tab­lished in the dis­trict in 2015, and clus­ters of en­ter­prises have been formed in skin­care prod­ucts, cos­met­ics, per­fumes, health prod­ucts and bio­med­i­cine.

“One in four fa­cial masks made in China is cur­rently pro­duced in Fengx­ian,” Wang said.

“I be­lieve the ‘Fengx­ian beauty val­ley’ will see an ob­vi­ous boost when it will be­come an ex­ten­sion of the Zhangjiang pharma val­ley,” he said.

The ac­tion plan said that Shang­hai’s goal was that the in­dus­try would reach 400 bil­lion yuan in 2020, and ap­pli­ca­tions for 50 drugs and 100 med­i­cal de­vices de­vel­oped in the city will be made be­fore be­ing mar­keted by that year.

It also said that the city aims to be­come a bio­med­i­cal in­no­va­tion source with in­dus­try clus­ters with in­ter­na­tional in­flu­ence by 2025.

Newspapers in English

Newspapers from Canada

© PressReader. All rights reserved.